Search results
Clive R. Wood, PhD is Corporate Senior Vice President and global head of Discovery Research at Boehringer Ingelheim. Before joining BI in April 2014, Clive was responsible for biologics research, process development and clinical manufacturing at Bayer HealthCare’s sites in Germany and the USA (2009-2014).
Corporate SVP, Global Head of Business Development & Licensing (BD&L) at Boehringer Ingelheim
- 500+
- 4K
- Boston, Massachusetts, United States
May 9, 2023 · Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers.
“Boehringer Ingelheim believes that these promising antibodies in-licensed from A*STAR will help us advance potent therapeutic candidates against key molecular cancer targets,” says Clive R. Wood, Senior Corporate Vice President and Global Head of Discovery Research at Boehringer Ingelheim and continues: “We look forward to developing ...
The AMAL team was delighted to welcome Clive Wood, Head of Global Discovery Research at #boehringeringelheim, for a very insightful and inspiring exchange on our cancer vaccine platform....
Dr. Clive Wood holds a PhD in Biochemistry from Imperial College London. He has been involved in pharmaceutical research and development since the 1980s, with a focus on developing antibody treatments for inflammation and cancer.
People also ask
Are You a driver of innovation at Boehringer Ingelheim?
Why is Boehringer Ingelheim launching a fibrotic trial?
Is Boehringer Ingelheim a leader in pulmonary fibrosis treatment?
What does Boehringer Ingelheim do?
Dr. Clive R. Wood, Head of Discovery Research. opnMe – A catalyst for scientific cooperation and collaboration.
